Tobias Thornblad

Synartro is a Swedish pharmaceutical company developing local injection treatments aiming to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our patented delivery technology with existing proven drugs. Our pre-clinical lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). Currently this disease leaves up to 50% of patients without adequate pain relief.

Synartro is a Swedish pharmaceutical company developing local injection treatments aiming to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our patented delivery technology with existing proven drugs. Our pre-clinical lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). Currently this disease leaves up to 50% of patients without adequate pain relief.

Monocl enables life science professionals work smarter with the right external stakeholders. We have developed Monocl, a cloud-based platform designed to help you collaborate and compete smarter. Monocl lets you find and engage with the right stakeholders, regardless if you are looking for scientific experts, investigators, medical institutions, customers or competitors. The platform contains millions of scientific experts and organizations, each seamlessly profiled to help you understand collaborations, research activities and financial transactions in a superior manner. Monocl is empowered by a machine-learning architecture currently based on source data from research publications, clinical trials, grant funding, industry payments and more. Visit www.monocl.com for more info.